This article has Open Peer Review reports available.
The plant coumarins auraptene and lacinartin as potential multifunctional therapeutic agents for treating periodontal disease
© Marquis et al.; licensee BioMed Central Ltd. 2012
Received: 2 March 2012
Accepted: 28 June 2012
Published: 28 June 2012
Periodontal diseases are bacterial infections leading to chronic inflammation disorders that are frequently observed in adults. In the present study, we evaluated the effect of auraptene and lacinartin, two natural oxyprenylated coumarins, on the growth, adherence properties, and collagenase activity of Porphyromonas gingivalis. We also investigated the capacity of these compounds to reduce cytokine and matrix metalloproteinase (MMP) secretion by lipopolysaccharide (LPS)-stimulated macrophages and to inhibit MMP-9 activity.
Microplate dilution assays were performed to determine the effect of auraptene and lacinartin on P. gingivalis growth as well as biofilm formation stained with crystal violet. Adhesion of FITC-labeled P. gingivalis to oral epithelial cells was monitored by fluorometry. The effects of auraptene and lacinartin on LPS-induced cytokine and MMP secretion by macrophages were determined by immunological assays. Fluorogenic assays were used to evaluate the capacity of the two coumarins to inhibit the activity of P. gingivalis collagenase and MMP-9.
Only lacinartin completely inhibited P. gingivalis growth in a complex culture medium. However, under iron-limiting conditions, auraptene and lacinartin both inhibited the growth of P. gingivalis. Lacinartin also inhibited biofilm formation by P. gingivalis and promoted biofilm desorption. Both compounds prevented the adherence of P. gingivalis to oral epithelial cells, dose-dependently reduced the secretion of cytokines (IL-8 and TNF-α) and MMP-8 and MMP-9 by LPS-stimulated macrophages, and inhibited MMP-9 activity. Lacinartin also inhibited P. gingivalis collagenase activity.
By acting on multiple targets, including pathogenic bacteria, tissue-destructive enzymes, and the host inflammatory response, auraptene and lacinartin may be promising natural compounds for preventing and treating periodontal diseases.
Periodontal diseases are chronic inflammatory disorders of bacterial origin that affect tooth-supporting tissues. It is estimated that 5% to 20% of any population suffers from severe, generalized periodontitis, while mild to moderate periodontitis affects a majority of adults. These diseases are mixed infections induced by a specific group of Gram-negative anaerobic bacteria called periodontopathogens. Of the over 700 bacterial species that have been identified in the oral cavity only a few are associated with periodontitis, including Porphyromonas gingivalis. This bacterial species produces a number of virulence factors that contribute to host colonization, immune defense system neutralization, and periodontal tissue destruction. High numbers of P. gingivalis, together with other periodontopathogens, induce a host immune response, which in turn leads to a destructive inflammatory process[6, 7].
Over the past two decades, there has been increasing interest in the potential human health benefits of natural compounds. Polyphenols, which are well known for their antioxidant properties, contribute to the protection of deoxyribonucleic acid (DNA) and macromolecules (lipids and proteins) and can prevent some types of cancers, cardiovascular diseases, and other disorders associated with oxidative stress[9, 10]. These natural compounds are members of a large class of organic molecules that are widely distributed in the plant kingdom and, as such, are an integral part of the daily diet of humans[11, 12]. Since polyphenols have been reported to possess antimicrobial and anti-inflammatory properties, they may be of interest as therapeutic agents for controlling periodontal diseases, which involve both pathogenic bacteria and host immune responses.
To the best of our knowledge, no one has investigated the potential beneficial effects of auraptene and lacinartin on oral health. We hypothesized that auraptene and lacinartin may be promising natural compounds that could be used to prevent and treat periodontal diseases. We thus evaluated the effects of these compounds on the growth, biofilm formation/desorption, and adherence to human oral epithelial cells of P. gingivalis. We also investigated their anti-inflammatory properties using a macrophage model as well as their ability to inhibit MMP-9 and P. gingivalis collagenase.
Materials and methods
Auraptene was purchased from Sigma-Aldrich Corp. (St. Louis, MO, USA). Lacinartin, an oxyisopentenylated coumarin, was produced using a previously reported procedure. Briefly, commercially available propiolic acid and pyrogallol were condensed by concentrated H2SO4 catalysis into daphnetin via a Pechmann reaction. The daphnetin was then selectively alkylated on position 7 of the coumarin ring with 3,3-dimethylallyl bromide and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU). It was then methylated on position 8 with methyl iodide and triethylamine to yield lacinartin. The final yield was 62%. Stock solutions of auraptene and lacinartin were prepared in dimethyl sulfoxide (10 mg/ml) and stored at 4°C in the dark.
Effect on Porphyromonas gingivalis growth
P. gingivalis ATCC 33277 was purchased from the American Type Culture Collection (Manassas, VA, USA). Bacteria were routinely grown in Todd-Hewitt broth (BBL Microbiology Systems, Mississauga, ON, Canada) supplemented with 20 μM hemin and 0.0001% vitamin K (THB-HK) at 37°C under anaerobic conditions (80% N2/10% H2/10% CO2) for 24 h. The effect of auraptene and lacinartin on P. gingivalis growth was assessed in two different culture media using a microplate dilution assay. THB-HK contained excess iron, while Mycoplasma broth base (MBB; BBL Microbiology Systems) supplemented with 10 μM hemin (MMB-H) contained limited iron. Briefly, 24-h cultures of P. gingivalis in THB-HK, or MBB-H were diluted in fresh broth medium to obtain an optical density of 0.2 at 660 nm (OD660). Equal volumes (100 μl) of P. gingivalis suspension and auraptene or lacinartin (0, 12.5, 25, 50, 100 μg/ml) in THB-HK, or MBB-H were mixed in the wells of 96-well plates (Sarstedt, Newton, NC, USA). Wells with no P. gingivalis, auraptene, or lacinartin were used as controls. After a 48-h incubation at 37°C under anaerobic conditions, bacterial growth was determined by measuring the OD660 using a microplate reader.
Effect on P. gingivalis biofilm formation/desorption
P. gingivalis was grown in THB-HK supplemented or not with auraptene or lacinartin as described above. After a 48-h incubation under anaerobic conditions, spent medium and free-floating bacteria were removed by aspiration using a 26 G needle, and the wells were washed three times with 50 mM phosphate-buffered saline (PBS) pH 7.0. The biofilms were stained with 100 μl of 0.02% crystal violet for 15 min. The wells were then washed three times with PBS to remove unbound dye and were dried for 2 h at 37°C. Ethanol (100 μl, 95% (v/v)) was added to the wells, and the plate was shaken for 10 min to release the dye from the biofilms. The absorbance at 550 nm (A550) was measured to quantify biofilm formation. We also investigated the capacity of auraptene and lacinartin to promote the desorption of a P. gingivalis biofilm. Briefly, a 48-h P. gingivalis biofilm was prepared as described above and was treated for 2 h with auraptene or lacinartin at final concentrations ranging from 0 to 100 μg/ml. The biofilms were stained with crystal violet as described above. All the above assays were performed in triplicate.
Effect on P. gingivalis adherence to oral epithelial cells
P. gingivalis cells were first labeled with fluorescein isothyocyanate (FITC). Briefly, a 10-ml aliquot of a 24-h culture (THB-HK) of P. gingivalis was centrifuged at 7000 x g for 10 min, and the pellet was suspended in 12 ml of 0.5 M NaHCO3 (pH 8) containing 0.03 mg/ml FITC. The bacterial suspension was incubated in the dark at 37°C for 30 min with constant shaking. The bacteria were then washed three times by centrifugation (7000 x g for 5 min) and were suspended in the original volume of PBS. The immortalized human oral epithelial cell line GMSM-K was kindly provided by Dr. Valerie Murrah (University of North Carolina, Chapel Hill, NC, USA). The epithelial cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 4 mM L-glutamine (HyClone Laboratories, Logan, UT, USA), 10% heat-inactivated fetal bovine serum (FBS; Sigma Aldrich Corp.), and 100 μg/ml of penicillin G/streptomycin at 37°C in a 5% CO2 atmosphere until they reached confluence. The cells were harvested by gentle trypsinization with 0.05% trypsin-ethylenediaminetetraacetic acid (Invitrogen, Grand Island, NY, USA) at 37°C and were suspended in DMEM (without FBS). Aliquots of cell suspension (100 μl, 1.5 x 106 cells/ml) were placed in the wells of 96-well black plates (Greiner Bio-One, St. Louis, MO, USA). After an overnight incubation to allow the formation a confluent monolayer, spent medium was aspirated, 100 μl of formaldehyde (3.7%) was added to the wells, and the plate was incubated at room temperature for 15 min. The formaldehyde was removed by aspiration and the wells were washed three times with PBS. Filtered 1% BSA (100 μl) was added to each well, and the plate was incubated for 30 min at 37°C in a 5% CO2 atmosphere. The wells were washed once with PBS, 100 μl of auraptene or lacinartin was added to each cell (final concentrations ranging from 0 to 100 μg/ml), and the plates were incubated for 30 min. The auraptene and lacinartin were not cytotoxic at these concentrations (data not shown). The FITC-labeled P. gingivalis cells were then added (100 μl) to the wells, and the plates were incubated in the dark for a further 90 min at 37°C under anaerobic conditions. Unbound bacteria were removed by aspiration, and the wells were washed three times with PBS. Relative fluorescence units (RUF; excitation wavelength 495 nm; emission wavelength 525 nm) corresponding to the degree of bacterial adherence were determined using a microplate reader. Control wells without auraptene or lacinartin were used to determine 100% adherence values. Wells containing only cells and auraptene or lacinartin were also prepared to determine the autofluorescence values of the two compounds. The assays were run in triplicate.
Anti-inflammatory properties in a macrophage model
U937 human monocytes (ATCC CRL-1593.2), a monoblastic leukemia cell line, were purchased from the American Type Culture Collection (Manassas, VA, USA). The cells were cultivated at 37°C in a 5% CO2 atmosphere in Roswell Park Memorial Institute 1640 medium (RPMI-1640; HyClone Laboratories) supplemented with 10% heat-inactivated FBS and 100 μg/ml of penicillin G/streptomycin. The monocytes (2.5 x 105 cells/ml) were then incubated in RPMI-FBS (1%) containing 10 ng/ml of phorbol myristic acid (PMA; Sigma Aldrich Corp.) for 48 h to induce differentiation into adherent macrophage-like cells. Following the PMA treatment, the medium was replaced with fresh medium, and the differentiated cells were incubated for an additional 24 h prior to use. The macrophages were incubated with auraptene or lacinartin (6.25 to 50 μg/ml) at 37°C in a 5% CO2 atmosphere for 2 h. They were then stimulated with 1 μg/ml of Aggregatibacter actinomycetemcomitans ATCC 29522 (serotype b) lipopolysaccharide (LPS) isolated using the procedure described by Darveau and Hancock. After a 24-h incubation at 37°C in a 5% CO2 atmosphere, the culture medium supernatants were collected and were stored at –20°C until used. Cells incubated in culture medium with or without auraptene or lacinartin but not stimulated with LPS were used as controls. Commercial enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems, Minneapolis, MN, USA) were used to quantify IL-8, TNF-α, MMP-8, and MMP-9 concentrations in the cell-free culture supernatants according to the manufacturer’s protocols. The absorbance at 450 nm was read using a microplate reader with the wavelength correction set at 550 nm.
Inhibition of MMP-9 and P. gingivalis collagenase activity
Human recombinant MMP-9 (active form) purchased from Calbiochem (San Diego, CA, USA) was diluted in reaction buffer (50 mM Tris-HCl, 150 mM NaCl, 5 mM CaCl2, and 0.02% Brij 35) to a concentration of 1 μg/ml and was incubated for 18 h in the absence or presence of auraptene or lacinartin (0-100 μg/ml) and fluorogenic substrate (100 μg/ml). To determine the effect of auraptene and lacinartin on P. gingivalis collagenase activity, a 48-h THB-HK culture was centrifuged at 10 000 x g for 10 min. The supernatant was then incubated for 18 h in the absence or presence of auraptene or lacinartin (0-100 μg/ml) and fluorogenic substrate (100 μg/ml). Gelatin DQTM and collagen DQTM (Molecular Probes, Eugene, OR, USA) were used to quantify MMP-9 and P. gingivalis collagenase activities, respectively. The assay mixtures were incubated for 18 h at 37°C for MMP-9 and at room temperature for P. gingivalis collagenase. The fluorescence was measured after 4 h using a microplate reader with the excitation and emission wavelengths set at 495 nm and 525 nm, respectively. Fluorescent substrates alone or with auraptene and lacinartin were used as controls. Specific inhibitors of MMP-9 (0.025 μM GM6001) and P. gingivalis collagenase (1 μM leupeptin) were tested. The assays were run in triplicate.
Results are expressed as the means ± standard deviations of three independent experiments. The data were analyzed using the Student’s t-test. A p value ≤ 0.05 was considered statistically significant.
Effect of auraptene and lacinartin on the activity of MMP-9 and P. gingivalis collagenase
MMP-9 (% activity)
Collagenase (% activity)
100 ± 1
100 ± 3
56 ± 1
6 ± 5
Auraptene 100 μg/ml
27 ± 1
110 ± 4
27 ± 1
113 ± 5
27 ± 3
113 ± 1
26 ± 1
107 ± 10
Lacinartin 100 μg/ml
19 ± 6
36 ± 3
25 ± 1
49 ± 1
31 ± 2
69 ± 1
26 ± 3
Periodontal diseases are polymicrobial infections and are the most common chronic inflammatory disorders in adults. Periodontitis is induced by a specific group of Gram-negative anaerobic bacteria and is the major cause of tooth loss in adults. Over the past two decades, natural compounds with antibacterial and anti-inflammatory properties have received considerable attention as new therapeutic agents for the treatment of periodontal infections. In this study, we investigated the potential of auraptene and lacinartin for preventing and treating periodontal diseases.
We first showed that lacinartin and to a lesser extent auraptene reduced P. gingivalis growth. This is the first report indicating that lacinartin possesses anti-bacterial properties. Previous studies have shown that auraptene has antibacterial properties against Helicobacter pylori[24, 25]. The exact mechanism by which lacinartin and auraptene inhibit bacterial growth is unknown. However, other natural coumarins (novobiocin and clorobiocin) inhibit deoxyribonuclease gyrase activity, which results in bacteria death[14, 26]. In addition, we showed that auraptene and lacinartin inhibit growth more effectively under iron-limiting conditions, requiring much lower concentrations to significantly reduce the growth of P. gingivalis. Our results are in agreement with those of Mladnka et al., who showed that coumarins possess iron-chelating properties. Additional studies are required to investigate interactions between iron and auraptene and lacinartin.
We also showed that lacinartin, but not auraptene, inhibits biofilm formation by P. gingivalis. Lacinartin also caused the desorption of a pre-formed P. gingivalis biofilm. To the best of our knowledge, this is the first report regarding the inhibitory effects of lacinartin on bacterial biofilms. Auraptene and lacinartin prevented the adherence of P. gingivalis to oral epithelial cells to a significant degree. Epithelial cells act as a physical barrier, and bacterial adherence to these host cells may be a critical step for the initiation of periodontal diseases. Given its ability to reduce growth of P. gingivalis and its adherence to epithelial cells, lacinartin may be a promising therapeutic candidate through its action on different targets.
Polyphenols reduce inflammatory mediator secretion and, as such, inflammation-mediated damage. We showed that auraptene markedly reduces IL-8 and TNF-α secretion by LPS-stimulated macrophages. Our results are in agreement with those of Genovese et al., who reported that auraptene inhibits the release of TNF-α by RAW 264.7 macrophages. To our knowledge, no one has investigated the anti-inflammatory properties of lacinartin. We showed that 12.5 μg/ml of lacinartin induced IL-8 and TNF-α secretion, likely due to a synergistic interaction between LPS and lacinartin. On the other hand, 50 μg/ml of lacinartin significantly inhibited IL-8 and TNF-α secretion. We also showed that auraptene and lacinartin reduced MMP-8 and MMP-9 secretion. These results are in agreement with those of a study by Epifano et al., who reported that auraptene inhibits MMP-7 secretion by HT-29 epithelial cells. Since MMP release and cytokine secretion are associated with tooth-supporting tissue destruction, our results suggested that both compounds may contribute to reducing host cell damage, including bone resorption[5, 31]. The mechanisms by which auraptene and lacinartin reduce inflammatory mediator secretion are unknown, but previous studies have shown that coumarins can block the activation of nuclear factor-κB and inhibit kinase pathways (Akt/PKB). Considering that gingival fibroblasts may also play a significant role in periodontal tissue destruction through cytokine-inducible MMP secretion, future studies should investigate the effects of auraptene and lacinartin on this cell type.
We further showed that auraptene and lacinartin reduce MMP-9 activity while only lacinartin inhibits P. gingivalis collagenase activity. Auraptene has previously been shown to inhibit MMP-7 activity. These observations suggest that these coumarins may contribute to reducing tissue destruction.
In conclusion, our study provided new information on auraptene and lacinartin indicating that they possess an array of interesting antimicrobial, anti-adhesion, anti-inflammatory and anti-protease properties that may be useful for the prevention and treatment of periodontal diseases. Since auraptene and lacinartin act on both etiologic factors of periodontal diseases (periodontopathogens and the host inflammatory response), they may be an alternative to traditional antimicrobials. Further studies are required to investigate the mechanisms of these coumarins, especially the mechanisms involved in their anti-inflammatory activity.
This study was financially supported by an International Association for Dental Research/GlaxoSmithKline Innovation in Oral Care Award.
- Highfield J: Diagnosis and classification of periodontal disease. Aust Dent J. 2009, 54 (Suppl 1): S11-26.View ArticlePubMedGoogle Scholar
- Burt B: Position paper: epidemiology of periodontal diseases. J Periodontol. 2005, 76 (8): 1406-1419.View ArticlePubMedGoogle Scholar
- Feng Z, Weinberg A: Role of bacteria in health and disease of periodontal tissues. Periodontol 2000. 2006, 40: 50-76. 10.1111/j.1600-0757.2005.00148.x.View ArticlePubMedGoogle Scholar
- Aas JA, Paster BJ, Stokes LN, Olsen I, Dewhirst FE: Defining the normal bacterial flora of the oral cavity. J Clin Microbiol. 2005, 43 (11): 5721-5732. 10.1128/JCM.43.11.5721-5732.2005.View ArticlePubMedPubMed CentralGoogle Scholar
- Holt SC, Ebersole JL: Porphyromonas gingivalis, Treponema denticola, and Tannerella forsythia: the "red complex", a prototype polybacterial pathogenic consortium in periodontitis. Periodontol 2000. 2005, 38: 72-122. 10.1111/j.1600-0757.2005.00113.x.View ArticlePubMedGoogle Scholar
- Garlet GP: Destructive and protective roles of cytokines in periodontitis: a re-appraisal from host defense and tissue destruction viewpoints. J Dent Res. 2010, 89 (12): 1349-1363. 10.1177/0022034510376402.View ArticlePubMedGoogle Scholar
- Kornman KS, Page RC, Tonetti MS: The host response to the microbial challenge in periodontitis: assembling the players. Periodontol 2000. 1997, 14: 33-53. 10.1111/j.1600-0757.1997.tb00191.x.View ArticlePubMedGoogle Scholar
- Pandey KB, Rizvi SI: Plant polyphenols as dietary antioxidants in human health and disease. Oxid Med Cell Longev. 2009, 2 (5): 270-278. 10.4161/oxim.2.5.9498.View ArticlePubMedPubMed CentralGoogle Scholar
- Scalbert A, Johnson IT, Saltmarsh M: Polyphenols: antioxidants and beyond. Am J Clin Nutr. 2005, 81 (1 Suppl): 215S-217S.PubMedGoogle Scholar
- El Gharras H: Polyphenols: food sources, properties and applications – a review. Int J Food Sci Technol. 2009, 44 (12): 2512-2518. 10.1111/j.1365-2621.2009.02077.x.View ArticleGoogle Scholar
- Bravo L: Polyphenols: chemistry, dietary sources, metabolism, and nutritional significance. Nutr Rev. 1998, 56 (11): 317-333.View ArticlePubMedGoogle Scholar
- Cos P, De Bruyne T, Hermans N, Apers S, Berghe DV, Vlietinck AJ: Proanthocyanidins in health care: current and new trends. Curr Med Chem. 2004, 11 (10): 1345-1359.View ArticlePubMedGoogle Scholar
- Genovese S, Epifano F: Auraptene: a natural biologically active compound with multiple targets. Curr Drug Targets. 2011, 12 (3): 381-386.View ArticlePubMedGoogle Scholar
- Borges F, Roleira F, Milhazes N, Santana L, Uriarte E: Simple coumarins and analogues in medicinal chemistry: occurrence, synthesis and biological activity. Curr Med Chem. 2005, 12 (8): 887-916. 10.2174/0929867053507315.View ArticlePubMedGoogle Scholar
- Komatsu S, Tanaka S, Ozawa S, Kubo R, Ono Y, Matsuda Z: Biochemical studies on grape fruits, Citrus aurantium. Nippon Kagaku Kaishi. 1930, 51: 478-498. 10.1246/nikkashi1921.51.478.View ArticleGoogle Scholar
- Nagao K, Yamano N, Shirouchi B, Inoue N, Murakami S, Sasaki T, Yanagita T: Effects of citrus auraptene (7-geranyloxycoumarin) on hepatic lipid metabolism in vitro and in vivo. J Agric Food Chem. 2010, 58 (16): 9028-9032. 10.1021/jf1020329.View ArticlePubMedGoogle Scholar
- Ogawa K, Kawasaki A, Yoshida T, Nesumi H, Nakano M, Ikoma Y, Yano M: Evaluation of auraptene content in citrus fruits and their products. J Agric Food Chem. 2000, 48 (5): 1763-1769. 10.1021/jf9905525.View ArticlePubMedGoogle Scholar
- Epifano F, Genovese S, Curini M: Auraptene: Phytochemical and pharmacological properties. Phytochemistry Research Progress. Edited by: Matsumoto T. 2008, Nova Science Publishers Inc, Hauppaughe,NY (USA), 145-162.Google Scholar
- Tanaka T, Kawabata K, Kakumoto M, Matsunaga K, Mori H, Murakami A, Kuki W, Takahashi Y, Yonei H, Satoh K: Chemoprevention of 4-nitroquinoline 1-oxide-induced oral carcinogenesis by citrus auraptene in rats. Carcinogenesis. 1998, 19 (3): 425-431. 10.1093/carcin/19.3.425.View ArticlePubMedGoogle Scholar
- Genovese S, Epifano F, Curini M, Dudra-Jastrzebska M, Luszczki JJ: Prenyloxyphenylpropanoids as a novel class of anticonvulsive agents. Bioorg Med Chem Lett. 2009, 19 (18): 5419-5422. 10.1016/j.bmcl.2009.07.110.View ArticlePubMedGoogle Scholar
- Darveau RP, Hancock RE: Procedure for isolation of bacterial lipopolysaccharides from both smooth and rough Pseudomonas aeruginosa and Salmonella typhimurium strains. J Bacteriol. 1983, 155 (2): 831-838.PubMedPubMed CentralGoogle Scholar
- Darveau RP: Periodontitis: a polymicrobial disruption of host homeostasis. Nat Rev Microbiol. 2010, 8 (7): 481-490. 10.1038/nrmicro2337.View ArticlePubMedGoogle Scholar
- Pihlstrom BL, Michalowicz BS, Johnson NW: Periodontal diseases. Lancet. 2005, 366 (9499): 1809-1820. 10.1016/S0140-6736(05)67728-8.View ArticlePubMedGoogle Scholar
- Epifano F, Menghini L, Pagiotti R, Angelini P, Genovese S, Curini M: In vitro inhibitory activity of boropinic acid against Helicobacter pylori. Bioorg Med Chem Lett. 2006, 16 (21): 5523-5525. 10.1016/j.bmcl.2006.08.043.View ArticlePubMedGoogle Scholar
- Takeda K, Utsunomiya H, Kakiuchi S, Okuno Y, Oda K, Inada K, Tsutsumi Y, Tanaka T, Kakudo K: Citrus auraptene reduces Helicobacter pylori colonization of glandular stomach lesions in Mongolian gerbils. J Oleo Sci. 2007, 56 (5): 253-260. 10.5650/jos.56.253.View ArticlePubMedGoogle Scholar
- Wu L, Wang X, Xu W, Farzaneh F, Xu R: The structure and pharmacological functions of coumarins and their derivatives. Curr Med Chem. 2009, 16 (32): 4236-4260. 10.2174/092986709789578187.View ArticlePubMedGoogle Scholar
- Mladenka P, Macakova K, Zatloukalova L, Rehakova Z, Singh BK, Prasad AK, Parmar VS, Jahodar L, Hrdina R, Saso L: In vitro interactions of coumarins with iron. Biochimie. 2010, 92 (9): 1108-1114. 10.1016/j.biochi.2010.03.025.View ArticlePubMedGoogle Scholar
- Andrian E, Grenier D, Rouabhia M: Porphyromonas gingivalis-epithelial cell interactions in periodontitis. J Dent Res. 2006, 85 (5): 392-403. 10.1177/154405910608500502.View ArticlePubMedGoogle Scholar
- Nijveldt RJ, van Nood E, van Hoorn DE, Boelens PG, van Norren K, van Leeuwen PA: Flavonoids: a review of probable mechanisms of action and potential applications. Am J Clin Nutr. 2001, 74 (4): 418-425.PubMedGoogle Scholar
- Genovese S, Curini M, Epifano F: Prenyloxyphenylpropanoids as a novel class of anti-inflammatory agents. Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry. 2010, 9 (2): 158-165.View ArticleGoogle Scholar
- Okada H, Murakami S: Cytokine expression in periodontal health and disease. Crit Rev Oral Biol Med. 1998, 9 (3): 248-266. 10.1177/10454411980090030101.View ArticlePubMedGoogle Scholar
- Kawabata K, Murakami A, Ohigashi H: Auraptene decreases the activity of matrix metalloproteinases in dextran sulfate sodium-induced ulcerative colitis in ICR mice. Biosci Biotechnol Biochem. 2006, 70 (12): 3062-3065. 10.1271/bbb.60393.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6882/12/80/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.